CD40LG and Sepsis: We aimed to prove the efficacy of intravenous IgM-enriched immunoglobulins by using indirect indicators of outcome; our hypothesis is that treated patients should benefit of a lower level of sepsis biomarkers (presepsin, endocan, pentraxin, plasmatic Nitric Oxide), compared to not treated subjects.